rovoctocogene durparvovec

Rovoctocogene durparvovec is an investigational gene therapy designed for the treatment of adults with severe hemophilia A. It uses an adeno-associated virus (AAV) vector to deliver a functional copy of the factor VIII gene to liver cells, enabling endogenous production of clotting factor VIII and thereby reducing or preventing bleeding episodes. The therapy aims to provide a long-term solution by allowing patients' own bodies to produce sufficient levels of factor VIII, potentially reducing or eliminating the need for regular infusions of exogenous clotting factors. Rovoctocogene durparvovec is being developed as part of efforts to address unmet needs in hemophilia A management by offering durable efficacy through a one-time intravenous administration.